ERNA
Ernexa Therapeutics Inc

11,003
Mkt Cap
$9.81M
Volume
51,272.00
52W High
$14.40
52W Low
$1.09
PE Ratio
-0.25
ERNA Fundamentals
Price
$1.20
Prev Close
$1.25
Open
$1.22
50D MA
$1.37
Beta
0.98
Avg. Volume
99,061.11
EPS (Annual)
-$48.97
P/B
2.64
Rev/Employee
$97,000.00
Loading...
Loading...
News
all
press releases
ERNA Stock Rallies On Collaboration With Contract Manufacturer To Advance Lead Cell Therapy Into Clinical Trials
The partnership will focus on activities to advance Ernexa’s lead cell therapy called ERNA-101 for the treatment of ovarian cancer into clinical manufacturing and trials.
Stocktwits·1mo ago
News Placeholder
More News
News Placeholder
Cellipont Bioservices and Ernexa Therapeutics Enter Cell Therapy Manufacturing Partnership to Advance ERNA-101 Toward Clinical Trials in Ovarian Cancer
Cellipont Bioservices and Ernexa Therapeutics Enter Cell Therapy Manufacturing Partnership to Advance ERNA-101 Toward Clinical Trials in Ovarian Cancer Cellipont Bioservices and Ernexa Therapeutics...
PR Newswire·1mo ago
News Placeholder
Ernexa Stock Drops On 1-For-15 Reverse Stock Split To Regain Nasdaq Compliance: Retail Sentiment Improves But Stays Bearish
As of Tuesday, the company had 110.4 million shares of common stock issued and outstanding, which it anticipates will result in approximately 7.4 million shares on a split-adjusted basis.
Stocktwits·6mo ago
News Placeholder
Eterna Therapeutics Announces the Appointment of Peter Cicala, JD, to its Board of Directors
CAMBRIDGE, Mass., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Eterna Therapeutics Inc. (Nasdaq: ERNA) ( Eterna or the Company ), a life science company committed to realizing the potential of mRNA cell...
Globe Newswire·2y ago
News Placeholder
Eterna Therapeutics Inc. (NASDAQ:ERNA) Short Interest Up 11.7% in January
Eterna Therapeutics Inc. (NASDAQ:ERNA Get Free Report) saw a large increase in short interest in January. As of January 31st, there was short interest totalling 147,900 shares, an increase of...
Ticker Report·2y ago
News Placeholder
Eterna Therapeutics files to sell 18.2M shares for holders
Eterna Therapeutics files to sell 18.2M shares for holders...
SeekingAlpha.com: All News·2y ago
News Placeholder
Eterna Therapeutics Grants New President and CEO Sanjeev Luther Inducement Award Under Nasdaq Listing Rule 5635 (c)(4)
CAMBRIDGE, Mass., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Eterna Therapeutics Inc. (Nasdaq: ERNA) ( Eterna or the Company ), a life science company committed to realizing the potential of mRNA cell...
Globe Newswire·2y ago

Latest ERNA News

View

Advertisement|Remove ads.

Advertisement|Remove ads.